Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.57 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25633974 | 0.80 | NLRP3 (0.65) | NLRP3THRBMAPTTP53SMN1; SMN2 | |
| SCHEMBL25633281 | 0.80 | NLRP3 (0.59) | NLRP3THRBMAPTTP53SMN1; SMN2 | |
| SCHEMBL25633958 | 0.79 | NLRP3 (0.62) | NLRP3THRBMAPTTP53SMN1; SMN2 | |
| SCHEMBL25633971 | 0.79 | NLRP3 (0.65) | NLRP3THRBMAPTTP53SMN1; SMN2 | |
| SCHEMBL23950515 | 0.79 | NLRP3 (0.52) | NLRP3MAPTPOLBTP53RXFP1 | |
| SCHEMBL25633344 | 0.78 | NLRP3 (0.61) | NLRP3THRBMAPTTP53RXFP1 | |
| SCHEMBL25633373 | 0.76 | THRB (0.76) | NLRP3THRBTP53SMN1; SMN2RXFP1 | |
| SCHEMBL30455823 | 0.74 | NLRP3 (0.55) | NLRP3THRBMAPTTP53RXFP1 | |
| SCHEMBL25633290 | 0.74 | NLRP3 (0.55) | NLRP3THRBMAPTTP53RXFP1 | |
| SCHEMBL30073546 | 0.74 | NLRP3 (0.59) | NLRP3THRBMAPTTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | NLRP3, NLRP1, PYCARD | NLRP3 1/4885THRB 277/4885MAPT 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.